| Altor BioScience Corporation – Product Pipeline Review – 2012 |
| Publication Date |
Jun 2012 |
| Publisher |
Global Markets Direct |
| Product Type |
Report |
| Pages |
51 |
| Single User License |
$
500.00 |
| Site User License |
$
1000.00 |
| Corporate User License |
$
1500.00 |
|
|
Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase. |
Altor BioScience Corporation – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Altor BioScience Corporation - Product Pipeline Review - 2012” provides data on the Altor BioScience Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Altor BioScience Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Altor BioScience Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Altor BioScience Corporation - Brief Altor BioScience Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Altor BioScience Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Altor BioScience Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Altor BioScience Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Altor BioScience Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Altor BioScience Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Altor BioScience Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Altor BioScience Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Altor BioScience Corporation and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Altor BioScience Corporation; Altor BioScience Corporation - Key Therapeutics; Altor BioScience Corporation - Pipeline Overview and Promising Molecules; Altor BioScience Corporation - News; Altor BioScience Corporation - Latest Updates; Altor BioScience Corporation - Pipeline; Altor BioScience Corporation - Discontinued/Dormant Projects
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Altor BioScience Corporation Snapshot 6
Altor BioScience Corporation Overview 6
Key Information 6
Key Facts 6
Altor BioScience Corporation – Research and Development Overview 7
Key Therapeutic Areas 7
Altor BioScience Corporation – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
Altor BioScience Corporation – Pipeline Products Glance 13
Altor BioScience Corporation Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Altor BioScience Corporation – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Altor BioScience Corporation – Drug Profiles 16
ALT-801 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
ALT-801 + Cisplatin 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ALT-801 + Gemcitabine + Cisplatin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ALT-802 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ALT-803 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ALT-804 24
Product Description 24
Mechanism of Action 24
R&D Progress 25
ALT-836 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ALT-836 + Gemcitabine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Antiviral TCR-Ck 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Antiviral TCR-Ig 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IL-15 Antagonist 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Altor BioScience Corporation – Pipeline Analysis 32
Altor BioScience Corporation – Pipeline Products by Therapeutic Class 32
Altor BioScience Corporation – Pipeline Products By Target 34
Altor BioScience Corporation – Pipeline Products by Route of Administration 35
Altor BioScience Corporation – Pipeline Products By Mechanism of Action 36
Altor BioScience Corporation – Recent Pipeline Updates 37
Altor BioScience Corporation – Locations And Subsidiaries 38
Head Office 38
Altor BioScience Corporation, Recent Developments 39
Altor BioScience Corporation- Press Release 39
Apr 30, 2012: Altor And Melanoma Research Alliance To Co-Support Clinical Studies Of ALT-803 To Treat Metastatic Melanoma 39
Sep 25, 2009: NCI Awards $3 MM SBIR Bridge Grant To Altor BioScience To Advance Clinical Trials For its Targeted Cancer Therapeutic ALT-801 39
Financial Deals Landscape 41
Altor BioScience Corporation, Deals Summary 41
Altor BioScience Corporation, Pharmaceuticals & Healthcare, Deal Details 42
Venture Financing 42
Altor Bioscience Secures $10.3 Million In Series D Financing 42
Altor Bioscience Secures $0.3 Million In Venture Financing Round 43
Altor BioScience Secures $1.2 Million In Series C1 Financing 44
Altor BioScience Secures $6 Million In Series C1 Financing 45
Altor BioScience Secures $15 Million In Series C Financing 46
Altor BioScience Completes Series B Financing 47
Partnerships 48
Altor BioScience Enters Into Licensing Agreement With Massachusetts General Hospital 48
Altor BioScience Enters Into Agreement With Massachusetts General Hospital And Howard Hughes Medical Institute 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51
List of TablesList of Tables
Altor BioScience Corporation, Key Information 6
Altor BioScience Corporation, Key Facts 6
Altor BioScience Corporation – Pipeline by Indication, 2012 8
Altor BioScience Corporation – Pipeline by Stage of Development, 2012 10
Altor BioScience Corporation – Monotherapy Products in Pipeline, 2012 11
Altor BioScience Corporation – Combination Treatment Modalities in Pipeline, 2012 12
Altor BioScience Corporation – Phase II, 2012 13
Altor BioScience Corporation – Phase I, 2012 14
Altor BioScience Corporation – Pre-Clinical, 2012 15
Altor BioScience Corporation – Pipeline By Therapeutic Class, 2012 33
Altor BioScience Corporation - Pipeline By Target, 2012 34
Altor BioScience Corporation – Pipeline By Route of Administration, 2012 35
Altor BioScience Corporation – Pipeline Products By Mechanism of Action, 2012 36
Altor BioScience Corporation – Recent Pipeline Updates, 2012 37
Altor BioScience Corporation, Deals Summary 41
Altor Bioscience Secures $10.3 Million In Series D Financing 42
Altor Bioscience Secures $0.3 Million In Venture Financing Round 43
Altor BioScience Secures $1.2 Million In Series C1 Financing 44
Altor BioScience Secures $6 Million In Series C1 Financing 45
Altor BioScience Secures $15 Million In Series C Financing 46
Altor BioScience Completes Series B Financing 47
Altor BioScience Enters Into Licensing Agreement With Massachusetts General Hospital 48
Altor BioScience Enters Into Agreement With Massachusetts General Hospital And Howard Hughes Medical Institute 49
List of FiguresList of Figures
Altor BioScience Corporation – Pipeline by Indication, 2012 8
Altor BioScience Corporation – Pipeline by Stage of Development, 2012 10
Altor BioScience Corporation – Monotherapy Products in Pipeline, 2012 11
Altor BioScience Corporation – Combination Treatment Modalities in Pipeline, 2012 12
Altor BioScience Corporation – Pipeline By Therapeutic Class, 2012 32
Altor BioScience Corporation - Pipeline By Target, 2012 34
Altor BioScience Corporation – Pipeline By Route of Administration, 2012 35
Altor BioScience Corporation - Pipeline Products By Mechanism of Action, 2012 36
| Title |
Date |
Price |
|
|
Jan 2013 |
$2000.00 |
|
|
Oct 2009 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
| 2011 U.S. Offices of Dentists Industry Report |
| By Barnes Reports |
| The Offices of Dentists Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2011 current and 2012 f ...Read More
|
|
Oct 2010 |
$149.00 |
|
|
May 2011 |
$149.00 |
|
|
Oct 2010 |
$149.00 |
|
|
May 2011 |
$149.00 |
|
|
Apr 2011 |
$149.00 |
|
|
Oct 2010 |
$149.00 |
|
|
May 2011 |
$149.00 |
|
| |
|
|
|
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
|
|
|
| |
|
| |
|
|
|
